Abstract:ID 130936 Poster Board 493 The receptor for pituitary adenylate cyclase-activating polypeptide (PACAP) is a Gs-coupled GPCR, designated PAC1. Antagonists of this receptor are being pursued for their potential to ameliorate atherosclerogenesis, depression, post-traumatic stress disorder, and migraine; discovery of agonists is also of interest for counteracting the neurodegenerative consequences of stroke and ischemia. However, obtaining small-molecule ligands (SMOLs) for this receptor has been challenging. Peptide-based antagonists include an N-terminally truncated version of PACAP38 (P38) itself, PACAP6-38 (P6-38). The activity of P6-38 as an antagonist is consistent with models of PACAP binding to PAC1 in which the N-terminus of PACAP is required for receptor activation leading to signaling through the Gs protein, while the C-terminus is involved in initial binding (affinity-trapping) to PAC1. P6-38 has been shown repeatedly to block the action of P38 as well as the naturally occurring ligand PACAP1-27 (P27) both in vivo and in cells expressing endogenous PAC1. Several SMOLs reported to be PAC1 antagonists in the literature were tested for antagonist activity in HEK293 cells expressing the human PAC1 receptor and a cAMP biosensor (CBS)-based cAMP detection system; however not only these but also P6 -38 were without inhibitory effect in this assay system. Accordingly, we re-tested the inhibitory activity of P6-38 against both P27 and P38 in cells expressing CBS but with native expression of PAC1: the rat NS-1 pheochromocytoma cell line, and the human SH-SY5Y neuroblastoma cell line. Both CBS-based luminescent read-out, and generation of cAMP provoked by exposure to EC50 concentrations of P27 or P38 (0.2 nM) were blocked by 1 mM P6-38 which also blocked downstream signaling effects (neuritogenesis) of P27 and P38. Recently, cryo-EM structures of a number of family B (secretin family) GPCR-ligand structures have been obtained, allowing detailed molecular dynamics analysis of ligand-receptor binding, and prediction of residues contributing most strongly to ligand engagement. Molecular dynamics simulations predicted initial receptor engagement with residues 6-30, but not 31-38, of P38. Accordingly, we synthesized a series of deletants of PACAP6-38 and tested their relative inhibitory potency in SH-SY5Y and NS-1 cells. PACAP6-30 (IC50 ~33 nM) was nearly as potent as PACAP6-38 (IC50 ~21 nM) as an inhibitor of cyclic AMP elevation by 0.2 nM P38 (the approximate EC50 for both the CBS-based and the direct cAMP assay, both carried out in the presence of phosphodiesterase inhibition by IBMX). PACAP6-27 was considerably less potent (IC 50 >10 mM). Thus, the affinity-trap model for PAC1-ligand interaction successfully predicts the behavior of peptide-based inhibitors of P27 and P38 engagement with an endogenously expressed PAC1 receptor. We are currently engaged in peptide modification of P6-30 in order to increase the potency of this PAC1 antagonist.

Expression, Identification and Biological Effects of the Novel Recombination Protein, Pacap38-Nta, with High Bioactivity

A New Recombinant PACAP-Derived Peptide Efficiently Promotes Corneal Wound Repairing and Lacrimal Secretion

The Distribution and Biological Fuction of Pituitary Adenylate Cyclase Activating Polypeptide

The TAT Peptide Endows PACAP with an Enhanced Ability to Traverse Bio-Barriers

Expression,Purification and Activity of Pituitary Adenylate Cyclase-activting Polypeptide 38 and Its Derivative

Gene Cloning and Expression of PACAP and Study of Its Biological Activity

Preparation and Activity Identification of Recombinant PACAP-PTD

Positive allosteric regulation of PAC1-R up-regulates PAC1-R and its specific ligand PACAP

Abstract P803: Pituitary Adenylate Cyclase-Activating Polypeptide via Cyclic-AMP Inhibits Nogo-A by Internalizing Its Receptor NgR1

Positive allosteric regulation of PAC1-R up-regulates<?A3B2 ACK?>PAC1-R and its specific ligand PACAP

Positive Allosteric Regulation of PAC1-R Up-Regulates&lt;?a3b2 ACK?&gt;PAC1-R and Its Specific Ligand PACAP

Neuropeptide Pacap in Mouse Liver Ischemia and Reperfusion Injury: Immunomodulation by the Camp-Pka Pathway

TAT-Mediated Protein Transduction of Nogo Extracellular Peptide 1-40 and Its Biological Activity

PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model

Expressions of endogenous pituitary adenylate cyclase-activating polypeptide following acute spinal cord injury in rats

Molecular Mechanism for PACAP 38-Induced Neurite Outgrowth in PC12 Cells

Pituitary Adenylate Cyclase Activating Polypeptide Elicits Neuroprotection Against Acute Ischemic Neuronal Cell Death Associated with NMDA Receptors

High-Level Expression, Purification, and Characterization of the Recombinant Grass Carp Pituitary Adenylate Cyclase-Activating Polypeptide

The Synthesis of PACAP and the Construction of Its Expression Vector

PACAP Deletants as Peptide-based PACAP Antagonists

Dimer-Dependent Intrinsic/Basal Activity of the Class B G Protein-Coupled Receptor PAC1 Promotes Cellular Anti-Apoptotic Activity Through Wnt/β-Catenin Pathways That Are Associated with Dimer Endocytosis